Heal Yourself At Home
GSE MELATONIN Health Benefits

MELATONIN is an anti-cancer agent

At present, the validity of MELATONIN as an oncostatic agent seems well established.    The antitumor mechanisms of MELATONIN have been identified, including:

✔ Anti-proliferative actions

✔ Immuno-stimulatory effects on host anti-cancer defenses

✔ Antioxidant activity.

Circulating levels of MELATONIN are depressed in a wide variety of cancers.    Including breast, endometrial, prostate, lung, gastric and colon.

Bartsch C, Bartsch H.MELATONIN in cancer patients and in tumor-bearing animals. Adv Exp Med Biol. 1999;467:247-64. PubMed

There are, however, isolated reports of tumor growth stimulation, especially if MELATONIN is administered in the morning.    Indicating a circadian-stage dependency of antitumor action.

Bartsch H, Bartsch C. Effect of MELATONIN on experimental tumors under different photoperiods and times of administration. J Neural Transm 1981;52:269–79.

A recent controlled trial shows the possibility to improve chemotherapy - in terms of both survival and quality of life of patients with advanced disease by a concomitant administration of MELATONIN and cisplatinium etoposide in metastatic non small cell lung cancer.

Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and MELATONIN:

Breast Cancer

–   Breast cancer risk was increased among subjects who frequently did not sleep during the period of the night when MELATONIN levels are typically at their highest.    There was also an indication of increased risk among subjects with the brightest bedrooms. Graveyard shiftwork was associated with increased breast cancer risk. Night shift work, Light at night, and Risk of breast cancer

–   Breast Cancer research clearly shows solid links between low late-night MELATONINand increased breastcancer cell growth.   A study demonstrated that MELATONIN-rich blood suppressed the growth of human breast cancer xenografts and rat hepatomas. No growth suppression occurred in tumors perfused with MELATONIN-deficient blood collected from the same women after short-term ocular exposure to bright light at night.

Blask DE et al. MELATONIN-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 2005 Dec 1;65(23):11174-84. Pub Med

–   CORTISOL levels are also tied to breast cancer risk.   Breast cancer patients with high average CORTISOL throughout the day and elevated CORTISOL at bedtime have earlier mortality, lower natural killer (NK) cell counts and decreased activity of NK cells The strength of the relationship between CORTISOL and MELATONINlevels

Sandra E. Sephton, Robert M. Sapolsky, Helena C. Kraemer, David SpiegelDiurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival. Oxford Journals MedicineJNCI Volume92, Issue12 Pp. 994-1000 JNCI

Reduced MELATONIN production has been proposed as a likely factor in the significantly higher cancer rates in night workers.   In 2007, The World Health Organization cited late night shift work as a probable cancer-causing agent. When someone works in artificial light, they generally have lower MELATONIN, and without this antioxidant and suppressant of tumor development, they may be more likely to develop cancer.

Straif, Kurt; Baan, Robert; Grosse, Yann; Secretan, BéAtrice; Ghissassi, Fatiha El; Bouvard, VéRonique; Altieri, Andrea; Benbrahim-Tallaa, Lamia et al. (2007). "Carcinogenicity of shift-work, painting, and fire-fighting". The Lancet Oncology 8(12): 1065–6.

Lower nocturnal MELATONIN levels are associated withlarger tumors in patients with primary prostate cancer

Vijayalaxmi, Charles R. Thomas, Jr, Russel J. Reiter, Terence S. Herman. MELATONIN: From Basic Research to Cancer Treatment Clinics.Journal of Clinical Oncology, Vol 20, Issue 10 (May), 2002: 2575-2601JOCO

Endogenous MELATONIN stimulates anti-cancer defenses and exhibits anti-proliferative and antioxidant activity

Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of MELATONIN.Sleep Med Rev. 2005 Feb;9(1):11-24. PubMed

side bar
DISCLAIMER: The content on this website is intended for informational, and educational purposes only and not as a substitute for the medical advice, treatment or diagnosis of a licensed health professional. The author of this website is a researcher, not a health professional, and shall in no event be held liable to any party for any direct, indirect, special, incidental, punitive or other damages arising from any use of the content of this website. Any references to health benefits of specifically named products on this site are this website author's sole opinion and are not approved or supported by their manufacturers or distributors. COPYRIGHT 2009-2019